Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some tumors progress ...

In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

The trial findings complement the updated US dyslipidemia guidelines that promote early and intensive LDL lowering.

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of ...

Researchers have announced a promising new oral medication capable of slashing harmful cholesterol more powerfully than standard statins, a potential breakthrough for more than 86 million Americans if ...

The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...